This resulted in an "erythrocyte fraction" beneath the percoll that contained the IC bound to erythrocytes, and a "plasma/buffy coat fraction" above the percoll that contained the IC in plasma and IC bound to buffy coat cells. Analysis of these data showed that the majority of the IC infused into the circulation rapidly became bound to erythrocytes. However, by 5 min after beginning the IC infusion, most of this IC load had been removed from the erythrocytes as they traversed the liver. In contrast, IC on erythrocytes did not deposit in kidney. The IC-bearing erythrocytes themselves were not trapped or detained by any organ. IC in the plasma/buffy coat fraction of blood were removed from the circulation but at a relatively low
INTRODUCTION
Complement receptor type 1 (CR1),' which has receptor specificity for the C3b and C4b components of the complement system, is present on the surface of human and other primate erythrocytes (1, 2) . The average number of CR, receptors per erythrocyte is small (mean < 2,000/cell) compared with that of circulating B lymphocytes, monocytes, and neutrophils where the average number of CR1 receptors per cell ranges from 21,000 to 148,000 (1) (2) (3) . However, because circulating erythrocytes greatly outnumber circulating leukocytes, the vast majority of all CR, receptors present uity in the vascular space, could play a role in the removal of circulating IC from the blood stream. The present study was undertaken to test that hypothesis. The results indicate that primate erythrocytes participate in a rapid and efficient mechanism for removal of large complement-fixing IC from the circulation.
METHODS

Preparation of IC
Crystallized bovine serum albumin (BSA, Sigma Chemical Co., St. Louis, MO) was labeled with 125I as previously described (10) . Labeling efficiency was -70% and specific activity ranged from 20 to 30 ,Ci/mg. Anti-BSA antibody was produced by immunizing New Zealand rabbits, as previously described (10) . The serum antibody concentration was measured by the quantitative precipitin method. IC were formed by combining at equivalence heat-inactivated rabbit antiserum with '251-labeled BSA ('25I-BSA), incubating for 1 h at 370C and then at 40C for 48 h. The resulting precipitate was centrifuged (1,200 g for 10 min), washed, and then incubated with 0.01 M phosphate-buffered saline (PBS, pH 7.2) to which five times excess of unlabeled BSA was added. The solution was agitated for 4 h at 370C, centrifuged (100 g for 20 min) , and the precipitate discarded. Approximately 5-30% of the precipitate was solubilized by this method, as assessed by loss of 1251 counts per minute from the precipitate. All IC preparations were made 24-48 h before use and were stored at 40C. This IC preparation was chosen for study because it showed much higher levels of complement-dependent binding to human and simian erythrocytes compared with IC preparations subjected to centrifugation at 500 or 1,000 g (8) .
To assess the extent to which the l25I-BSA was incorporated into IC, 1 ml of 20% polyethylene glycol 6000 (PEG) was added to 10 Al of IC solution. This concentration of PEG precipitates >90% of the l'2I-BSA that is incorporated into IC, but <10% of the '251-labeled BSA that is not incorporated into IC (12) . By this procedure -90% of lssI-BSA was in the form of IC.
Surgical preparation
Seven primates (three female rhesus monkeys, one male, and three female baboons) were used. The animals weighed 5.4-30.2 kg. Anesthesia was induced by intramuscular administration of Ketamine and atropine. An endotracheal tube was then inserted and anesthesia maintained with inhalation of halothane and nitrous oxide. Electrocardiographic monitoring was maintained throughout the experiment. Intravenous Ringer's lactate was infused continuously at 1-3 ml/min, depending on body size. Under sterile conditions (four experiments) or nonsterile conditions (three experiments) the common femoral artery and vein of both lower extremities were isolated to facilitate angiographic catheter placement. An upper midline abdominal incision was then made to provide exposure of the portal vein in the porta hepatis. A No. 5 French polyethylene feeding tube was then placed in the portal vein through a stab incision and stabilized with a 6.0 polypropylene suture. The animal was then transferred to the fluoroscopy room where an angiographic catheter (5 or 6 French with torque control) was placed, under fluoroscopic guidance and with the aid of infusion of contrast media, into each of the following locations: the ascending aorta just above the aortic valve, the abdominal aorta at the level of the renal arteries, the renal vein (right or left), and a right hepatic vein. The aortic arch catheter was used for periodic measurement of arterial blood pressure, for infusion of the IC and, in three experiments, for infusion of '%Sr-labeled microspheres (15±0.8 um, 3 M Company, St Paul, MN) to assess tissue blood flow. The remaining catheters made it possible to monitor changes in blood composition across kidney (arterial vs. renal vein blood), across liver (arterial + portal vein vs. hepatic vein blood) and across the portal circulation (arterial vs. portal vein blood). The portal vein provides the venous drainage of the spleen, stomach, small bowel, large bowel, and pancreas. Hereafter, these organs will be simply referred to as spleen + gut.
Experimental protocol
Animals were infused with autologous 51Cr-labeled erythrocytes as follows: [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ml of blood were removed, the erythrocytes isolated, washed in Hanks' balanced salt solution, labeled with 20-40 sCi of 51Cr (10) , washed, infused, and allowed to circulate for a minimum of 20 min. 10-20 ml of IC (0.3-2.2 mg) were then infused at a steady rate with a hand-held syringe over 120 s. Blood samples (-1 ml) were drawn simultaneodsly from the catheters in the abdominal aorta, hepatic, portal, and renal veins into tuberculin syringes that contained 10 U of heparin. The blood samples were drawn starting at time 0, at 20-s intervals until 120 s had elapsed, and then at 3, 4, 5, 15, and 30 min. Each blood sample was transferred to an iced tube immediately after it was drawn. The tubes remained iced until processed as described below. All processing of these blood samples was done within 2 h of completing the experiment. Arterial blood pressure was monitored immediately before starting the IC infusion and at 5 and 30 min into the experiment. After obtaining the last (30 min) blood specimen, the position of the catheters in the aortic arch, renal vein, and hepatic vein was reassessed angiographically. In no experiment did catheter displacement occur. In the four experiments performed under sterile surgical conditions, the arteriotomy and venotomy incisions were then sutured and the animals allowed to recover from the general anesthesia. In the three experiments performed under nonsterile conditions, 1-2 gCi of 8sSr-labeled micropheres were infused into the aortic arch catheter and, after 2-3 min had elapsed, the animals were sacrificed by infusion of pentobarbital. To determine the content of each isotope in each organ, an aliquot (510%) was taken from liver, kidney, spleen, stomach, large bowel, small bowel, pancreas, and lung and the isotope counts per minute determined as described previously (11 (13) . Briefly, exponential gradients were formed of [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .25% sucrose (wt/wt, isokinetic at 20'C) using a constant volume mixing chamber (kindly provided by Dr. Ronald Taylor, Department of Biochemistry, University of Virginia School of Medicine). The gradients (total gradient volume = 4.8 ml) were placed in a temperature-regulated ultracentrifuge (model L8-55, Beckman Instruments, Inc., Palo Alto, CA) and equilibrated at 20'C. To determine the population of IC that bind to baboon erythrocytes the following three reaction mixtures were prepared in duplicate: (a) fresh serum + IC + erythrocytes; (b) fresh serum + IC + PBS; and (c) heat-inactivated serum + IC + erythrocytes. After 10 min at 370C, each reaction mixture was placed on percoll and centrifuged at 350 g for 15 min. After centrifugation, the material above the percoll was removed, the 125I counts per minute determined and then placed on the 15-24.25% isokinetic sucrose gradients. The gradients were centrifuged at 1,500 rpm for 30 min (w2t = 4.39 X 107 rad2/s) at 20'C. The gradients were then removed and fractionated via bottom displacement with 35% sucrose. 0.2-ml fractions were collected (total of 25 fractions) and 125I counts per minute determined. The 251I counts per minute of each fraction was then plotted against the sedimentation coefficient (S20, w) corresponding to each sucrose fraction. Fractional removal of IC from erythrocytes traversing liver or kidney or spleen + gut. This was determined as follows: the 1251 counts per minute of the erythrocyte fractions of the blood entering and leaving the given organ were plotted as a function of time. The time course of IC removal from the erythrocyte fraction was divided into an early phase (0-5 min) and a late phase (5-30 min). 5 min was chosen as the dividing line since the period of 0-5 min corresponded to the period of the greatest rate of removal of IC from the blood (Results). The area under the early phase curve of the 125I counts per minute on erythrocytes entering (A) and leaving (B) the given organ was then determined. The fraction of the '25I-labeled IC removed during the early phase was then calculated as (A -B)/A. The late phase fractional removal of IC from erythrocytes was calculated as the ratio: 1 -(mean 125I cpm on erythrocytes leaving the organ at the 5, 15, and 30 min time points)/(mean 125I cpm on erythrocytes entering the given organ at the 5, 15, and 30 min time points). This simpler formula was used for the late phase calculation because, in general, the late phase values represented low and nearly steady-state values with only small differences between the 1251 counts per minute on the erythrocytes entering and leaving the given organ.
Calculations
The IC on erythrocytes entering and leaving the kidney were taken as the 1251 counts per minute in the erythrocyte fractions of the arterial and renal venous blood samples, respectively. The IC on erythrocytes entering and leaving spleen + gut were taken as the 125I counts per minute in the erythrocyte fractions of the arterial and portal venous blood samples, respectively. To determine the IC on erythrocytes entering liver (via hepatic artery and portal vein), the following corrections were applied to the '25I counts per minute in the erythrocyte fraction of each hepatic artery and portal 238 Cornacoff, Hebert Fractional removal of IC from the nonerythrocyte fraction of blood (plasma/buffy coat fraction). To determine the extent to which IC were removed from the blood by mechanisms other than the erythrocyte-IC-clearing mechanism, the 1251 content of the entire percoll fraction of each blood specimen was measured and plotted vs. time. These data were then analyzed exactly as was done for the erythrocyte fractions of blood, as discussed above. The percoll fractions contained l25I-labeled IC free in the plasma, 125I1 labeled IC bound to leukocytes and platelets, and the i25I-BSA free in the plasma. Hereafter, this fraction of blood will be referred to as the plasma/buffy coat fraction.
Fraction of total hepatic blood flow via the hepatic artery. This fraction was taken as the ratio: (total microsphere cpm in liver)/(total microsphere cpm in liver + spleen + stomach + large bowel + small bowel + pancreas). The rationale for this calculation is that the microspheres in liver represent hepatic artery blood flow, while the microspheres in spleen + gut + pancreas represent blood flow to the liver via the portal vein (11 Vascular space correction. To determine the extent to which the tissue '25I counts represent '25I-labeled IC actually deposited in tissues vs. '25I-labeled material, which is simply passively retained in the vascular space at the time the tissues were excised, a correction factor based on the 51Cr counts in the vascular space and '25I counts in whole blood was applied as follows: '25I cpm deposited in tissue = 125I cpm/ g of tissue -(51Cr cpm/g of tissue) X (125I cpm/g of whole blood)/(51Cr cpm/ml of whole blood), as described previously (14) .
Hemodynamic data. Mean systolic blood pressure at the start of the experiment was 82±6 mmHg and was stable during the experiment. Mean hematocrit at the start of the experiment was 33±4% and decreased by -5% during the experiment due to the volume of blood samples removed and saline infused. In no instance was hemolysis noted. RESULTS
Clearance of preformed IC
The results of a representative experiment are shown in Figs. 2 and 3. As can be seen from comparison of the 125I counts per minute in the arterial blood erythrocyte fraction (Fig. 2) to the 125I counts per minute in the arterial blood plasma/buffy coat fraction (Fig.  3) , the majority of the '25I-labeled IC infused into the arterial blood become bound to erythrocytes. Furthermore, as the IC-bearing erythrocytes traverse liver the great majority of their IC burden is deposited. This Fig. 2 Fig. 4 . 51Cr-Labeled erythrocytes bind IC in vitro to the same extent as do erythrocytes not subjected to the process of 51Cr-labeling (Fig. 5) . Thus, under these conditions, the behavior of the 51Cr-labeled erythrocytes is representative of the general erythrocyte population.
The spleen appears to function in the same manner as the liver as shown by the fact that the l25I-labeled IC are efficiently removed from the erythrocytes traversing the organs served by the portal vein (spleen + gut) and, as shown below, most of the IC deposited in spleen + gut are deposited in spleen. The 51Cr-labeled erythrocytes are not detained by the spleen.
The handling of IC-bearing erythrocytes by kidney stands in striking contrast to that of the liver. By comparing the '25I counts per minute in arterial blood to that of renal vein, it is evident that the IC-bearing erythrocytes exit kidney with IC burden virtually intact (Fig. 2) .
The handling of the plasma/buffy coat fraction of blood by liver, kidney, and spleen + gut is shown in (11) . Thus, there is no evidence of selective removal of 51Cr-labeled erythrocytes from the circulation. If this had occurred, even in a subtle fashion, the calculated tissue vascular allowance would have been inappropriately high (10).
Isokinetic sucrose density gradient analysis of IC
To determine the size of the IC used in these experiments and the size of IC which bind to erythrocytes, in vitro experiments were performed using erythrocyte suspensions depleted of buffy coat cells before incubation with IC. These experiments are depicted and described in Fig. 6 . As can be seen, IC ranging in size from 10,000 S to >288,000 S are present in the original IC preparation and this range of IC sizes was only slightly affected by incubation in fresh serum. The entire range of IC bound to erythrocytes. However, the percent of IC bound to erythrocytes increased markedly with increasing IC size.
Search for evidence of the erythrocyte-IC-clearing mechanism under conditions in which IC can form in vivo Two additional experiments were performed to determine whether the operation of the erythrocyte-ICclearing mechanism could be detected when IC are allowed to form in vivo by infusing antigen and antibody separately into the same animal. In one experiment antigen was infused first, followed 15 min later by antiserum. In the other experiment, the order of infusion was reversed. The proportion of antigen and antibody was that which approximated equivalence. In all other respects the protocol was the same as described in Methods. In both experiments <4% of the 1251 counts per minute were found in the erythrocyte fraction. On the basis of the experiment in which 1251_ BSA was infused first, it could be determined that this small amount of erythrocyte-associated 125I could be attributed to nonspecific binding. Throughout both experiments whole blood 1251 counts per minute fell gradually, after the BSA infusion was completed, probably largely reflecting the diffusion of 1251-BSA into the interstitial spaces. There was negligible removal of '251-labeled material from either the erythrocyte or plasma/buffy coat fractions traversing liver or kidney. Thus, the erythrocyte-IC-clearing mechanism, or any other IC-clearing mechanism, was not detected in either of these experiments. Although negative, these experiments are useful since they show that specific hepatic removal of albumin ('251-BSA) from the circulation (15) cannot explain the high rate of hepatic removal from the circulation of the preformed IC used in this study. These experiments also suggest that future studies to elucidate the operation of the erythrocyte-IC-clearing mechanism will require the use of specific populations of preformed IC since the percent binding to erythrocytes of IC forming in vivo appears to be very low. DISCUSSION This study demonstrates that when large, complementfixing IC are infused into the blood stream of primates, the great majority of these IC rapidly become bound to circulating erythrocytes. The mechanism of adherance of IC to erythrocytes in vivo is currently under investigation in our laboratory. However, in vitro, it has been shown that the binding of IC to primate erythrocytes is complement dependent (6) (7) (8) (9) . It is generally thought that C3b sites are generated on the IC, which then allow the IC to bind to erythrocyte CR1 receptors. C3b sites on IC are generated very rapidly. For example, previous studies have shown that, in vivo, C3b sites are generated on IgM-sensitized erythrocytes so rapidly that only liver blood flow limits the rate at which the sensitized erythrocytes are removed from the circulation by the C3b receptors of the hepatic mononuclear phagocyte system (16 (18, 19) . Thus, the erythrocyte is not damaged by attachment to the IC. Indeed, in vitro studies have shown that if IC are cleaved from the erythrocyte by prolonged exposure to the complementdependent release activity of fresh serum (20) , the erythrocyte is, once again, able to bind IC (21) .
Although IC-bearing erythrocytes can be demonstrated to aggregate in vitro (immune adherence reaction [6] If the first step in the hepatic uptake of erythrocytebound IC is the binding of the IC to hepatic macrophage C3b and/or Fc receptors, the second step is the breaking free of the erythrocyte from the macrophagebound IC. This could occur mechanically, because of the force of blood flow on the relatively rigid erythrocyte causes the erythrocyte to tear free from its attachment to the hepatic macrophage. If the total force binding the IC to the hepatic macrophage is greater than the total force binding the IC to the erythrocyte, the erythrocyte will break free leaving the IC bound to the hepatic macrophage. Alternatively, C3b inactivator or some other enzyme could cleave the bond between IC and erythrocytes. Indeed, Medof et al. (22) have shown that erythrocyte CR1 receptor markedly enhance the activity of C3b inactivator. Thus, it seems possible that a synergistic interaction between mechanical and enzymatic factors in liver could be responsible for the extremely efficient uptake of erythrocyte-bound IC by liver.
In contrast to the rapid hepatic removal of IC from the erythrocyte fraction of blood, the hepatic removal of IC from the plasma/buffy coat fraction of blood was considerably slower. This could reflect strong binding or phagocytosis of IC by peripheral blood leukocytes rendering the IC unavailable to the hepatic mononuclear phagocytes. It is also possible that the IC in the plasma phase represent a population of smaller IC that are cleared by the liver less efficiently than are larger IC (23, 24) .
The preformed IC used as the biological probe in this study are much larger than are those used traditionally and were chosen simply because they showed the highest level of binding to primate erythrocytes in vitro. The biological significance of such large IC is not clear. However, Cameron (25) (27) have shown that preformed BSA-anti-BSA IC smaller ('200 S) than those used in the present study can bind to primate erythrocytes in vitro. However, high dilution of the complement source (1:8 to 1:16 dilution of serum) is needed for maximum binding of these smaller IC (9) .
In this study, IC binding to erythrocytes was not detected in vivo when free antigen and antibody were infused separately. This, however, may simply indicate that IC of sufficient size to permit binding to erythrocytes form at a rate which is too low and/or are cleared too quickly to be detected under the present experimental conditions. Thus, studies to elucidate further the operation of the erythrocyte-IC-clearing mechanism will apparently also require the use of specific populations of preformed IC.
The erythrocyte-IC-clearing mechanism is, evidently, largely an adaptation of man and other primates. Lower forms of animals have some ability of their erythrocytes to bind to IC, possibly through Fc receptors (28) or antibody-aggregated C4 receptors (29) . However, only primates have vast numbers of CR1 receptors on circulating erythrocytes. The present study demonstrates the existence in primates of a potentially important erythrocyte-IC-clearing mechanism and provides a teleologically satisfying explanation for the existence of the vast numbers of CR1 receptors on circulating erythrocytes. Failure or insufficiency of the erythrocyte-IC-clearing mechanism might increase the probability of deposition of IC in vulnerable organs, such as kidney, and concomitantly decrease the probability of safe disposal of IC in liver or spleen. Indeed, this may occur in patients with systemic lupus erythematosus who have deficient numbers of erythrocyte CR1 receptors (3, 30, 31) or in whom the erythrocyte CR1 receptors are occupied by IC (32, 33) . Thus, inadequacy of the erythrocyte-ICclearing mechanism could play an important role in the clinical expression of systemic lupus erythematosus and other diseases mediated by deposition of circulating IC. 246 Cornacoff, Hebert, Smead, VanAman, Birmingham, and Waxman
